Qiagen wins Singapore contract for bird flu test kits

14 January 2008

Venlo, Netherlands-based diagnostics giant Qiagen has been awarded an exclusive contract by the Singapore Ministry of Health to supply sample preparation solutions and molecular tests for the specific detection of influenza H5N1 viruses - better known as avian flu.

For the country's preparedness program, Qiagen provides both fully-automated and manual sample preparation technologies for the extraction of viral nucleic acids. These are complemented by test kits for specific and sensitive detection of the highly pathogenic avian influenza strain. The contract runs for three years and the volume depends on minimum stockpiling levels, as well as the level of intensity of the country's surveillance program.

The contract with the Singapore Ministry of Health is the latest supply agreement of Qiagen with public and private institutions engaged in H5N1 surveillance. More than 80 institutes worldwide involved in the detection of avian flu infection use procedures and reagents developed and offered by the Dutch firm.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight